Company / Operating Cash Flow
Arcutis Biotherapeutics, Inc. Operating Cash Flow History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$5.6M
FY2025
5-year range
-$257.7M / -$5.6M
FY2021-FY2025
Trend
+95.0%
vs FY2024
Sector context
#79 of 216
Health Care
What the data says
At -$6M, Arcutis Biotherapeutics, Inc.'s operating cash flow ranks #79 of 216 in the Health Care sector. Operating Cash Flow has increased for 3 consecutive years, from -$258M in FY2022 to -$6M in FY2025.
Based on SEC 10-K filings.
-$6M in FY2025.
Improved from -$247M to -$6M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#79 of 216 in Health CareTop 37% of 216This company -$5.6M Sector average $659.0M
▼
-100.9% below sector average
Key checks
Key Insights
- Arcutis Biotherapeutics, Inc.'s operating cash flow has grown for 3 consecutive years.
- In FY2025, operating cash flow increased 95.0% year-over-year.
- Ranks #79 out of 216 companies in the Health Care sector.
- Lowest operating cash flow in the period was in FY2022.
Company context
Key Data Points
- Altman Z-Score -0.65 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$5.6M | +95.0% |
| FY2024 | -$112.2M | +54.6% |
| FY2023 | -$247.1M | +4.1% |
| FY2022 | -$257.7M | -47.6% |
| FY2021 | -$174.6M | -54.5% |
| FY2020 | -$113.0M | -163.9% |
| FY2019 | -$42.8M | -204.1% |
| FY2018 | -$14.1M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026